David Brown

seragon biosciences

H指数:28

被引数:4,600

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SRN-901; a Novel Longevity Drug; Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways

SRN-901; 一种新型长寿药物; 通过靶向多种衰老通路延长寿命和健康寿命

drug design; development and therapy

IF0

2026-04-150

OAAI

Bortezomib for the treatment of anti-N-methyl-d-aspartate receptor encephalitis in a patient with psoriatic arthritis receiving adalimumab: A case report and literature review

硼替佐米治疗接受阿达木单抗治疗的一名银屑病关节炎患者抗N-甲基-D-天冬氨酸受体脑炎：病例报告及文献综述

Journal of Neuroimmunology

IF2.5

2025-09-090

OAAI

Application of platform process development approaches to the manufacturing of MabcalinTM bispecifics

JOURNAL OF BIOTECHNOLOGY

IF3.9

2023-11-014

OAAI

Diarylurea compounds inhibit caspase activation by preventing the formation of the active 700-kilodalton apoptosome complex

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-03-2755

OAAI

Targeting NOX2 via p47/phox-p22/phox Inhibition with Novel Triproline Mimetics

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2022-05-107

Reply to: 'Respiratory harms from vaping: Questions for debate and discussion'

RESPIROLOGY

IF6.3

2021-12-080

OAAI

When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis

ENDOCRINE PRACTICE

IF4.6

2021-12-0114

OAAI

A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode

具有新型结合模式的甲基转移酶PRMT5的化学探针

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2020-09-2814

OAAI

A systematic review and meta-analysis of haematological malignancies in residents living near petrochemical facilities

ENVIRONMENTAL HEALTH

IF5.9

2020-07-0934

OAAI

Doxorubicin Exposure Causes Subacute Cardiac Atrophy Dependent on the Striated Muscle-Specific Ubiquitin Ligase MuRF1

jacc heart failure

IF8.4

2019-03-0194

OAAI

Prevention of Relapse in Schizophrenia: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306

BIOLOGICAL PSYCHIATRY

IF9

2018-05-012

PREAI

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

评估新型磷酸二酯酶9抑制剂BI 409306在精神分裂症认知障碍中的疗效，安全性和耐受性: 一项随机，双盲，安慰剂对照的II期试验

SCHIZOPHRENIA BULLETIN

IF4.8

2018-05-0127

OAAI

Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4

NADPH氧化酶Nox4抑制剂的设计、合成及生物学评价

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2018-03-0127

OAAI

A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia

NEUROLOGY AND THERAPY

IF4.8

2017-11-246

OAAI

Caring for a patient with rabies: implications of the Milwaukee protocol for infection control and public health measures

照顾狂犬病患者: 密尔沃基协议对感染控制和公共卫生措施的影响

JOURNAL OF HOSPITAL INFECTION

IF3.1

2017-08-011

OAAI

Cessation of biomechanical stretch model of C2C12 cells modelsmyocyte atrophy and anaplerotic changes in metabolism usingnon-targeted metabolomics analysisAmro (vol 79, pg 80, 2016)

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

IF2.8

2017-07-012

PREAI

Ubiquitin Ligases and Posttranslational Regulation of Energy in the Heart: The Hand that Feeds

COMPREHENSIVE PHYSIOLOGY

IF5.2

2017-06-1810

PREAI

The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2016-11-0467

OAAI

Transcranial doppler re-screening of subjects who participated in STOP and STOP II

AMERICAN JOURNAL OF HEMATOLOGY

IF9.9

2016-10-2514

OAAI

Cessation of biomechanical stretch model of C2C12 cells models myocyte atrophy and anaplerotic changes in metabolism using non-targeted metabolomics analysis

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

IF2.8

2016-10-0116

OAAI

David Brown

个人简介

教育背景

工作经历

荣誉奖项

研究方向